Skip to main content
Premium Trial:

Request an Annual Quote

Caprotec Raises $5M in Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – German protein reagents and sample prep technology firm Caprotec Bioanalytics said yesterday that it has closed on a €4 million ($5 million) Series B financing round.

Proceeds will be used to further develop its Capture Compound Mass Spectrometry technology for analyzing complex protein mixtures, the firm said in a statement. Specifically, Caprotec will continue development of its caproKits for the identification of functionally selected protein classes, as well as its ImproMed application for profiling drug interactions.

Participants in the financing included existing investors Creathor Venture, IBB Beteiligungsgesellshaft, ERP Startfonds, and private investors, the Berlin-based company said.

Caprotec's technology, called CCMS, is based on tri-functional molecules called capture compounds, and can be used to define and confirm drug targets and to discover off-target proteins that cause side effects.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.